Literature DB >> 22577112

Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome.

Dalhia Abramovich1, Griselda Irusta, Diana Bas, Natalia Isabel Cataldi, Fernanda Parborell, Marta Tesone.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinological pathology among women of reproductive age. It is characterized by anovulation, oligo- or amenorrhea, hyperandrogenism, obesity, and insulin resistance. PCOS patients present with elevated levels of vascular endothelial growth factor (VEGF) in serum and follicular fluid. In this study, we examined the ovarian expression of angiopoietins (ANGPT) and their receptor tyrosine kinase receptor (TIE2), involved in the stabilization of blood vessels, in a rat model of dehydroepiandrosterone-induced PCOS. We also analyzed the effect of ovarian VEGF inhibition on ANGPT/TIE2, follicular development, and vascular stability. VEGF levels were increased in the PCOS ovaries, whereas the levels of its receptor fetal liver kinase-1 were decreased. In addition, the periendothelial cell area and the ANGPT1 to ANGPT2 ratio in the ovary were increased in the PCOS group. Percentage of primary follicles was increased and the percentage of preantral follicles and corpora lutea was decreased in the PCOS group. VEGF inhibition decreased the percentage of primary follicles close to control values. Interestingly, despite the presence of cysts in the ovaries from VEGF inhibitor-treated PCOS rats, its percentage was lower than the PCOS group without treatment. In summary, this study describes an alteration not only in the VEGF/fetal liver kinase-1 system but also in the ANGPT/TIE2 system in a dehydroepiandrosterone-induced PCOS rat model. This leads to an increase in periendothelial cell recruitment. We also demonstrated that ovarian VEGF inhibition can partially restore the accumulation of small follicles in PCOS rats and reduces cyst formation, improving ovulation and follicular development. Therefore, the inhibition of VEGF could be considered, in addition to other currently applied treatments, as a new strategy to be studied in PCOS patients to restore ovarian function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577112     DOI: 10.1210/en.2012-1105

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Fab fragment glycosylated IgG may play a central role in placental immune evasion.

Authors:  Jiang Gu; Yu Lei; Yuanping Huang; Yingying Zhao; Jing Li; Tao Huang; Junjun Zhang; Juping Wang; Xiaodong Deng; Zhengshan Chen; Christine Korteweg; Ruishu Deng; Meiling Yan; Qian Xu; Shengnan Dong; Monghong Cai; Lili Luo; Guowei Huang; Yun Wang; Qian Li; Changmei Lin; Meng Su; Chunzhang Yang; Zhengping Zhuang
Journal:  Hum Reprod       Date:  2014-12-11       Impact factor: 6.918

Review 2.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

3.  High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.

Authors:  Minna Sopo; Hanna Sallinen; Kirsi Hämäläinen; Annukka Kivelä; Seppo Ylä-Herttuala; Veli-Matti Kosma; Leea Keski-Nisula; Maarit Anttila
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

4.  The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis.

Authors:  Kata Osz; Michelle Ross; Jim Petrik
Journal:  Reprod Biol Endocrinol       Date:  2014-03-14       Impact factor: 5.211

5.  The local effects of ovarian diathermy in an ovine model of polycystic ovary syndrome.

Authors:  Fiona Connolly; Michael T Rae; Mairead Butler; Alexander L Klibanov; Vassilis Sboros; Alan S McNeilly; W Colin Duncan
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

6.  Assessment of growth and metabolism characteristics in offspring of dehydroepiandrosterone-induced polycystic ovary syndrome adults.

Authors:  Ying Huang; Jiang-Man Gao; Chun-Mei Zhang; Hong-Cui Zhao; Yue Zhao; Rong Li; Yang Yu; Jie Qiao
Journal:  Reproduction       Date:  2016-12       Impact factor: 3.906

7.  Altered Circulating Inflammatory Cytokines Are Associated with Anovulatory Polycystic Ovary Syndrome (PCOS) Women Resistant to Clomiphene Citrate Treatment.

Authors:  LianLian Wang; HongBo Qi; Philip N Baker; QianNa Zhen; Qing Zeng; Rui Shi; Chao Tong; Qian Ge
Journal:  Med Sci Monit       Date:  2017-03-01

8.  Reduced Angiopoietin-2 as a Predictive Biomarker for Clomiphene Citrate Resistance in Polycystic Ovary Syndrome.

Authors:  Luxmipratha Rajendiran; Hanumanthappa Nandeesha; Thyagaraju Chitra
Journal:  J Hum Reprod Sci       Date:  2021-06-28

9.  The effect of androgens on ovarian follicle maturation: Dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPARγ-dependent PTEN expression.

Authors:  Mei-Jou Chen; Chia-Hung Chou; Shee-Uan Chen; Wei-Shiung Yang; Yu-Shih Yang; Hong-Nerng Ho
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

10.  Dehydroepiandrosterone Ameliorates Abnormal Mitochondrial Dynamics and Mitophagy of Cumulus Cells in Poor Ovarian Responders.

Authors:  Chia-Jung Li; San-Nung Chen; Li-Te Lin; Chyi-Uei Chern; Peng-Hui Wang; Zhi-Hong Wen; Kuan-Hao Tsui
Journal:  J Clin Med       Date:  2018-09-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.